CRISPR base editing of ANGPTL3 achieves durable lipid reduction
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
A single-course treatment using a CRISPR adenine base editor encapsulated in lipid nanoparticles achieves liver-selective inactivation of ANGPTL3. In nonhuman primates, a single dose led to a greater than 90 percent reduction in circulating ANGPTL3 protein, with durability confirmed up to three years.
Continue in the app — vote & join in ➔Source: Nature News · via ahirlevel.hu